en · de · es · fr · pt
hplc-notes.peptides6088.com › Data › Thymosin Beta-4 Fragment Overview — Reference Sheet

Thymosin Beta-4 Fragment Overview — Reference Sheet

By Editorial Desk · published 2026-07-02 · last reviewed 2026-08-01 · Data

This is a working overview of Peptide content, written for readers who want more than a one-paragraph summary but less than a textbook.

Reviewed 2026-08-01. Anything still debated is marked as such rather than presented as settled.

Thymosin Beta-4 Fragment Overview

Proposed activity centers on actin sequestration and on the movement of cells during repair processes. In cell culture and animal models, the fragment has been associated with migration, tube formation, and tissue remodeling. These observations are frequently described as preliminary, because most published work uses rodent or in vitro systems rather than controlled human trials. Whether the short fragment reproduces the effects of the full protein remains an open question, and the relationship between dose, route, and measured outcome is not well characterized.

The compound circulates in the literature as a research reagent rather than an approved therapeutic. Regulatory agencies in several countries have not authorized it for medical use, and sporting bodies list related thymosin beta-4 peptides among prohibited substances. Suppliers typically market it with a purity figure and a certificate of analysis, while peer-reviewed clinical reports remain sparse. Discussions therefore often separate laboratory findings from anecdotal reports, and reviewers tend to note the small size and methodological limits of the available studies.

TB-500 refers to a synthetic peptide fragment derived from the actin-binding region of thymosin beta-4, a protein present in most mammalian cells. The full protein contains forty-three amino acids, while the commonly sold fragment is a much shorter acetylated sequence, often cited as LKKTETQ. The fragment retains part of the actin-binding motif but lacks the remainder of the parent protein. Material sold under this name is usually lyophilized powder intended for laboratory research, and it is not a finished pharmaceutical product.

Thymosin Beta-4 Fragment Identity

No major regulatory agency has approved TB-500 for therapeutic use, and it holds no pharmacopoeial monograph. The name appears on the World Anti-Doping Agency prohibited list within the class covering peptide hormones, growth factors, and related substances. Detection in doping control relies on mass spectrometric methods applied to urine, often after preparation steps that concentrate the analyte. Discussion of TB-500 therefore clusters in biochemistry, sports medicine, and anti-doping literature rather than in registered clinical trials.

TB-500 is a synthetic peptide preparation marketed under a name derived from thymosin beta-4, a 43-residue actin-binding protein first isolated from thymus tissue. The full-length protein has a reported molecular mass near 4963 Da, while material sold as TB-500 is often described as a fragment containing the actin-binding motif LKKTETQ. Because suppliers use the name inconsistently, published sources sometimes refer to the same label as a fragment, a synthetic copy, or a related analog. This naming ambiguity complicates direct comparison of reports across studies.

Tb-500 at a glance

PropertyValueNotes
AppearanceWhite to off-white powderLyophilized solid as supplied
Water solubilitySolubleDissolves in aqueous media
Typical storage temperature-20 °CDry powder, desiccated, protected from light
Typical analytical methodRP-HPLC with mass spectrometryPurity from peak area; mass for identity
Common synonymsTβ4 fragment; thymosin beta-4 fragmentNaming varies by supplier and catalogue

Research Framing and Evidence Base

Controlled human trials of the short fragment are scarce. Much of what appears in review articles is extrapolated from animal models or from studies of the parent protein, and literature searches return a larger body of cardiac and ophthalmic work on thymosin beta-4 than on the abbreviated peptide. Regulatory treatment differs by jurisdiction, and in several countries the material is handled as a research chemical rather than an approved therapeutic. Statements about human benefit should be read as provisional.

Biological interest in this peptide centers on its relationship to actin dynamics. Thymosin beta-4 binds monomeric actin through an LKKTET motif, and a short sequence carrying that motif can compete with other actin-binding proteins in cell-free preparations. Investigators propose that such competition shifts the balance between filament assembly and disassembly, which in turn affects how readily a cell extends protrusions and migrates. Most of the supporting observations come from cultured cells and purified protein systems rather than from intact organisms.

Related pages on this site

Storage, Handling, and Analytical Checks

Purity and identity are separate measurements and are often confused. Reverse-phase high-performance liquid chromatography, usually with ultraviolet detection near 214 nanometres, reports the share of total peak area belonging to the target compound. Mass spectrometry by electrospray or matrix-assisted laser desorption then checks whether the observed mass matches the expected sequence. Neither measurement alone shows that a vial holds the intended peptide. Peptide content, meaning the fraction of vial mass that is genuine peptide rather than counter-ion, water or residual acid, is reported separately and is frequently lower than the stated purity figure.

The regulatory position is broadly consistent across major jurisdictions: no thymosin beta-4 fragment is an approved medicine, and laboratory material is commonly labelled as not intended for human consumption. Anti-doping rules in sport list thymosin beta-4 and its fragments among prohibited peptide hormones. Because these products travel through research-chemical channels rather than pharmaceutical supply chains, quality varies considerably between vendors. Independent testing of identity, purity and sterility is the only dependable check, and a certificate of analysis describes one batch rather than a supplier's whole catalogue.

Lyophilized peptide powder is normally held desiccated at −20 °C, with −80 °C used for longer storage periods. Allowing a sealed vial to reach room temperature before opening is standard practice, because condensation forming on cold powder introduces moisture. Once dissolved, solutions are typically kept cold and shielded from light. Repeated freeze-thaw cycles are avoided because they encourage aggregation and gradual loss of material. These conventions are general to synthetic peptides rather than unique to any one sequence.

TB-500 Identity and Chemical Background

TB-500 is a laboratory label applied to a short synthetic peptide that is widely described as a fragment of thymosin beta-4, an actin-binding protein present in most mammalian cells. Suppliers and review articles usually present TB-500 as the N-terminal region of that protein, but the exact sequence attached to the name is not consistent across sources. Some product descriptions list a seven-residue chain; others use the label loosely for the parent protein itself. Because of that variation, any technical discussion of TB-500 needs to state which sequence is meant.

Thymosin beta-4 contains 43 amino acids and has a reported molecular mass near 4963 Da. The short fragment most often associated with the TB-500 label, an acetylated chain beginning LKKTETQ, has a reported mass near 889 Da, so the two are easily separated in analytical work. Mass spectrometry and amino acid analysis can confirm which material is present in a given sample. Statements treating TB-500 and thymosin beta-4 as interchangeable are therefore imprecise, even though the two appear together in much of the same literature.

TB-500 Identity and Molecular Background

Several names appear in scientific and commercial contexts for this peptide. The label TB-500 is informal and does not follow standard biochemical nomenclature. Research articles more often describe the compound as a thymosin beta-4 fragment, Tβ4 fragment, or by its sequence Ac-LKKTETQ. Confusing TB-500 with full-length thymosin beta-4 can lead to incorrect assumptions about activity because the fragment lacks the remaining residues of the parent protein. The relationship between fragment and parent protein remains an active area of study.

Regulatory status differs by country, but TB-500 is not an approved pharmaceutical in major jurisdictions. It is commonly sold as a research chemical for laboratory use, which places responsibility for identity and purity on the supplier and the laboratory. Published human data are limited, and most reports involve preclinical models or cell culture. Questions about whether the fragment mimics all actions of thymosin beta-4, and under which conditions, remain open. Independent verification of any material is therefore a practical requirement in research settings.

TB-500 is a synthetic heptapeptide with the sequence Ac-LKKTETQ. It corresponds to a short N-terminal region of thymosin beta-4, a 43-amino-acid protein found in many cell types. The fragment contains an actin-binding motif, which is one reason it appears in laboratory studies of cell migration and cytoskeletal dynamics. TB-500 is not the full-length protein and is produced as a research chemical rather than an approved therapeutic agent. Its molecular weight is approximately 889 Da.

Background from the literature

demonstrated DE sorting and isolation on-chip followed by FACS that allows for high sorting throughput of encapsulated mammalian cells, from which genetic material can later be extracted. While fluorogenic labeling is a powerful tool for tracking and sorting, it is not always compatible with droplet-based microfluidic systems and experimental design. New label-free and non-fluorescence-based detection techniques have recently been reported. In 2016, Gielen et al. published an absorbance-activated droplet sorting (AADS) microfluidic device and demonstrated its functionality by directing the evolution of a phenylalanine dehydrogenase. In 2016, Sun et al. demonstrated the use of SE droplets and high-throughput MS to screen enzyme activators and inhibitors by screening a transaminase library. In 2019, Pan et al. showed sorting of droplets by interfacial tensions, which are affected by droplet content. In 2020, Haidas et al. presented a microfluidic approach that uses both matrix-assisted laser desorption ionization mass spectrometry (MALDI-MS) and fluorescence microscopy, which the authors used to measure the concentration and activity of phytase, respectively, in yeast cells. In 2020, Holland-Moritz et al. published their mass activated droplet sorting (MADS) method, which integrates MS analysis with fluorescence-activated droplet sorting (FADS). Using this method, droplets are split and analyzed separately by both MS and FADS. The power of this method was demonstrated by screening the activity of a transaminase library expressed in vitro.

Lauren Saunders of the National Consumer Law Center and Andrew Kushner of the Center for Responsible Lending criticized sponsor MoneyLion, a financial tech and cash advance company, for advertising to a young audience, which Kushner said were more susceptible to "the slick marketing" of the finance industry. Jeff Yang similarly argued that the sponsorship would allow MoneyLion's owner, Gen Digital, to target groups in MrBeast's audience facing "dire economic precarity". Some critics have analyzed the political implications of the show. According to Yang, while Squid Game was creating contextual critiques of oligarchs and exploiting disadvantaged people, Beast Games is unwittingly glorifying these concepts. Patrick Freyne of The Irish Times compared the giving away of islands to contestants in the fifth episode to colonialism. In response to IGN's negative review, Donaldson wrote "Yeah, sad one person who doesn't like me can just label something a thousand people poured their lives into a 2 out of 10 when it's clearly not." Donaldson similarly questioned the gap between audience and critic scores on Rotten Tomatoes.

"It would seem that you have now finally closed the door which you publicly claimed to have opened." Amid frantic efforts by Beadle and others on both sides to revive the Royal Commission, the Rhodesian government had Gibbs announce a state of emergency the same day on the grounds that black Rhodesian insurgents were reportedly entering the country. Smith denied that this foreshadowed a declaration of independence, but the publishing of his letter to Wilson in the press provoked a worldwide storm of speculation that UDI was imminent. Smith wrote again to Wilson on 8 November, asking him to appoint the Royal Commission under the terms they had agreed in Salisbury and to commit the British government to accepting its ruling, but Wilson did not immediately reply. On 9 November, the Rhodesian Cabinet sent a letter to Queen Elizabeth II, assuring her that Rhodesia would remain loyal to her personally "whatever happens".

=== Competitive and ecological roles === Beyond these interactions, Xanthoria parietina often overgrows other epilithic lichens without affecting their photobionts. It also supports microbial communities beneath its thallus, likely benefiting from microhabitats created by its attachment structures. In addition, Xanthoria parietina plays a role in biogeochemical cycling by promoting rock weathering through hyphal penetration and adhesion. Its interactions with minerals such as quartz, feldspar, and muscovite contribute to mineral breakdown, particularly in carbonate-rich substrates. Finally, the lichen competes with other foliose lichens. In experimental settings, it showed competitive equivalence with Parmelia caperata but was overgrown by Parmelia saxatilis under some conditions. In three-species mixtures, however, X. parietina often gained a competitive advantage—possibly due to its tolerance for elevated nitrogen levels. Its ability to thrive in nutrient-rich environments may allow it to outcompete acidophytic species in habitats influenced by agricultural or atmospheric nitrogen inputs. When competing with other lichens, X. parietina typically forms codominant relationships rather than completely displacing other species, particularly in early colonization stages. Field studies show that when X. parietina thalli border upon other lichens such as Physcia species, neither distinctly overgrows the other, but rather their marginal lobes intermingle. The frequent co-occurrence of X. parietina with grey-colored Physcia species may represent more than simple cohabitation.

== Further reading == Brayden DJ (November 2022). "Localised Delivery of Macromolecules to the Large Intestine: Translation to Clinical Trials". BioDrugs. 36 (6): 687–700. doi:10.1007/s40259-022-00562-6. PMID 36282433. S2CID 253109130.</ref> Fourie A, Cheng X, Chang L, Greving C, Patrick A, Knight B, et al. (October 2023). "S1028 Characterization of a First-in-Class Oral Therapy Selectively Targeting the IL-23 Pathway". American Journal of Gastroenterology. 118 (10S): S781. doi:10.14309/01.ajg.0000953752.29003.56. Ghusn W, Gala K, Rahme SJ, Salame M, Mrad R, Abboud DM, et al. (October 2023). "S1029 Disparities in Age, Sex, Race, and Ethnicity in Clinical Trials Focused on Inflammatory Bowel Disease in the United States". American Journal of Gastroenterology. 118 (10S): S781–S782. doi:10.14309/01.ajg.0000953756.85659.9e. Rusiñol L, Carmona-Rocha E, Puig L (3 July 2023). "Psoriasis: a focus on upcoming oral formulations". Expert Opinion on Investigational Drugs. 32 (7): 583–600. doi:10.1080/13543784.2023.2242767. PMID 37507233. S2CID 260286273.

Sources: en.wikipedia.org

Reference notes

As for the southern part of the street, Via Roma ends in Piazza Carlo Felice and in its Giardino Sambuy, a wide fenced garden right in the middle of the square. Across from Piazza Carlo Felice stands the monumental façade of Porta Nuova railway station, the central station of the city built between 1861 and 1868 by the architect Alessandro Mazzucchetti. The passengers building was renovated to host a shopping mall and more efficient passenger service offices. However, it is still an example of monumental architecture, with its stately foyer and some Baroque sights, such as the Sala Reale (the former Royal waiting room).

=== 6 December === The Governor of Kursk Oblast in Russia, Roman Starovoyt, claimed that a Ukrainian drone attack destroyed an oil tank near an airbase. No reports of casualties and the fire was under control. There was no comment from Ukraine on these claims.

== Distribution == Acanthurus coeruleus is present in the western Atlantic Ocean from New York to Florida, Mexico and Brazil, and Ascension Island in the Mid-Atlantic. Also found in the Mediterranean Sea since 2011.

=== Transport properties === Transport properties such as diffusivity describe how rapidly molecules move through the polymer matrix. These are very important in many applications of polymers for films and membranes. The movement of individual macromolecules occurs by a process called reptation in which each chain molecule is constrained by entanglements with neighboring chains to move within a virtual tube. The theory of reptation can explain polymer molecule dynamics and viscoelasticity.

When cultivated for human consumption in Western nations, insects are held to the same safety requirements as any other food. Depending on the popularity in a given location, processing might be done commercially or locally. The procedure begins with the removal of the insect's insides, albeit this step is optional. They are then dispatched to be preserved or freeze-dried, which is accomplished using hessian or polypropylene. They are transported for storage once they have been entirely preserved/dried. Insects can be frozen or ground into powders. Cricket flour is produced from freeze-dried crickets. The crickets are then cooked to facilitate processing. They are pulverized into extremely fine bits after being cooked. The freezing, baking, and drying results in a powdered dark brown flour. Insect flour is one of Whole Foods Market's banned ingredients in the U.S., with cricket flour being specifically mentioned on their paper bags.

Sources: en.wikipedia.org

Frequently asked questions

What is TB-500?

TB-500 is a name used for a short synthetic peptide fragment taken from the actin-binding region of thymosin beta-4. Material sold under this label is usually a lyophilized powder supplied for laboratory research rather than a licensed medicine. The commonly cited sequence is LKKTETQ.

How does it differ from full thymosin beta-4?

The parent protein contains forty-three amino acids, while the fragment carries only a short motif from one region. The fragment can interact with actin in vitro, but it does not include the rest of the protein structure. Whether the shorter molecule behaves the same way in living systems is not settled.

Is human evidence available?

Published controlled human studies are scarce, and most activity reports come from cell culture or animal models. Reviews often describe the evidence base as limited and methodologically uneven. Open questions include the relationship between route, dose, and measured outcomes.

Is TB-500 the same as thymosin beta-4?

Not necessarily. TB-500 is a commercial label that suppliers apply to synthetic peptides described as thymosin beta-4 or a fragment of it. Published research most often studies the full-length protein, so statements about one do not automatically transfer to the other.

Network